Research ExplorerPublicationsPlatelet P2Y12 Inhibitor Monotherapy after Percutaneous Coro...

Platelet P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention: An Emerging Option for Antiplatelet Therapy De-escalation

Standard

Platelet P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention: An Emerging Option for Antiplatelet Therapy De-escalation. / Verheugt, Freek W A; Huber, Kurt; Clemmensen, Peter; Collet, Jean-Philippe; Cuisset, Thomas; Andreotti, Felicita.

In: THROMB HAEMOSTASIS, Vol. 123, No. 2, 02.2023, p. 159-165.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Verheugt, FWA, Huber, K, Clemmensen, P, Collet, J-P, Cuisset, T & Andreotti, F 2023, 'Platelet P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention: An Emerging Option for Antiplatelet Therapy De-escalation', THROMB HAEMOSTASIS, vol. 123, no. 2, pp. 159-165. https://doi.org/10.1055/s-0042-1755330

APA

Verheugt, F. W. A., Huber, K., Clemmensen, P., Collet, J-P., Cuisset, T., & Andreotti, F. (2023). Platelet P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention: An Emerging Option for Antiplatelet Therapy De-escalation. THROMB HAEMOSTASIS, 123(2), 159-165. https://doi.org/10.1055/s-0042-1755330

Vancouver

Verheugt FWA, Huber K, Clemmensen P, Collet J-P, Cuisset T, Andreotti F. Platelet P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention: An Emerging Option for Antiplatelet Therapy De-escalation. THROMB HAEMOSTASIS. 2023 Feb;123(2):159-165. https://doi.org/10.1055/s-0042-1755330

Bibtex

@article{2ac598cd04934fd7a27be73929eda796,
title = "Platelet P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention: An Emerging Option for Antiplatelet Therapy De-escalation",
abstract = "Antiplatelet therapy is considered essential for secondary prevention of ischemic heart disease. After percutaneous coronary intervention (PCI), temporary dual antiplatelet therapy (DAPT), a combination consisting of aspirin and an oral P2Y12 receptor blocker, is recommended. In the long term, this strategy results in more bleeding than antiplatelet therapy with aspirin alone. Therefore, to reduce bleeding, an increasing trend has been to keep DAPT as short as clinically acceptable, after which aspirin monotherapy is continued. Another option to diminish bleeding is to discontinue aspirin at the moment of DAPT cessation after PCI, and to continue on P2Y12 blocker monotherapy. This survey reviews the evidence on P2Y12 blocker monotherapy. Some clinical guidance will be provided on when and in whom P2Y12 inhibitor monotherapy may be applied after DAPT cessation following PCI.",
keywords = "Humans, Platelet Aggregation Inhibitors/therapeutic use, Percutaneous Coronary Intervention/methods, Purinergic P2Y Receptor Antagonists/therapeutic use, Aspirin/therapeutic use, Dual Anti-Platelet Therapy/methods, Hemorrhage/prevention & control, Drug Therapy, Combination, Treatment Outcome",
author = "Verheugt, {Freek W A} and Kurt Huber and Peter Clemmensen and Jean-Philippe Collet and Thomas Cuisset and Felicita Andreotti",
note = "Thieme. All rights reserved.",
year = "2023",
month = feb,
doi = "10.1055/s-0042-1755330",
language = "English",
volume = "123",
pages = "159--165",
journal = "THROMB HAEMOSTASIS",
issn = "0340-6245",
publisher = "Schattauer",
number = "2",

}

RIS

TY - JOUR

T1 - Platelet P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention: An Emerging Option for Antiplatelet Therapy De-escalation

AU - Verheugt, Freek W A

AU - Huber, Kurt

AU - Clemmensen, Peter

AU - Collet, Jean-Philippe

AU - Cuisset, Thomas

AU - Andreotti, Felicita

N1 - Thieme. All rights reserved.

PY - 2023/2

Y1 - 2023/2

N2 - Antiplatelet therapy is considered essential for secondary prevention of ischemic heart disease. After percutaneous coronary intervention (PCI), temporary dual antiplatelet therapy (DAPT), a combination consisting of aspirin and an oral P2Y12 receptor blocker, is recommended. In the long term, this strategy results in more bleeding than antiplatelet therapy with aspirin alone. Therefore, to reduce bleeding, an increasing trend has been to keep DAPT as short as clinically acceptable, after which aspirin monotherapy is continued. Another option to diminish bleeding is to discontinue aspirin at the moment of DAPT cessation after PCI, and to continue on P2Y12 blocker monotherapy. This survey reviews the evidence on P2Y12 blocker monotherapy. Some clinical guidance will be provided on when and in whom P2Y12 inhibitor monotherapy may be applied after DAPT cessation following PCI.

AB - Antiplatelet therapy is considered essential for secondary prevention of ischemic heart disease. After percutaneous coronary intervention (PCI), temporary dual antiplatelet therapy (DAPT), a combination consisting of aspirin and an oral P2Y12 receptor blocker, is recommended. In the long term, this strategy results in more bleeding than antiplatelet therapy with aspirin alone. Therefore, to reduce bleeding, an increasing trend has been to keep DAPT as short as clinically acceptable, after which aspirin monotherapy is continued. Another option to diminish bleeding is to discontinue aspirin at the moment of DAPT cessation after PCI, and to continue on P2Y12 blocker monotherapy. This survey reviews the evidence on P2Y12 blocker monotherapy. Some clinical guidance will be provided on when and in whom P2Y12 inhibitor monotherapy may be applied after DAPT cessation following PCI.

KW - Humans

KW - Platelet Aggregation Inhibitors/therapeutic use

KW - Percutaneous Coronary Intervention/methods

KW - Purinergic P2Y Receptor Antagonists/therapeutic use

KW - Aspirin/therapeutic use

KW - Dual Anti-Platelet Therapy/methods

KW - Hemorrhage/prevention & control

KW - Drug Therapy, Combination

KW - Treatment Outcome

U2 - 10.1055/s-0042-1755330

DO - 10.1055/s-0042-1755330

M3 - SCORING: Journal article

C2 - 36584699

VL - 123

SP - 159

EP - 165

JO - THROMB HAEMOSTASIS

JF - THROMB HAEMOSTASIS

SN - 0340-6245

IS - 2

ER -